Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease
10.1111/j.1525-1497.2004.30090.x Cite this article as: Shekelle, P.G., Morton, S.C., Jungvig, L.K. et al. J GEN INTERN MED (2004) 19: 380. doi:10.1111/j.1525-1497.2004.30090.x Abstract OBJECTIVE: To evaluate and synthesize the evidence on the effect of supplements of vitamin E on the prevention and treatment of cardiovascular disease. DESIGN: Systematic review of placebo-controlled randomized controlled trials; meta-analysis where justified. MEASUREMENTS AND MAIN RESULTS: Eighty-four eligible trials were identified. For the outcomes of all-cause mortality, cardiovascular mortality, fatal or nonfatal myocardial infarction, and blood lipids, neither supplements of vitamin E alone nor vitamin E given with other agents yielded a statistically significant beneficial or adverse pooled relative risk (for example, pooled relative risk of vitamin E alone=0.96 [95% confidence interval (CI), 0.84 to 1.10]; 0.97 [95% CI, 0.80 to 1.90]; and 0.72 [95% CI, 0.51 to 1.02] for all-cause mortality, cardiovascular mortality, and nonfatal myocardial infarction, respectively. CONCLUSIONS: There is good evidence that vitamin E supplementation does not beneficially or adversely affect cardiovascular outcomes. Key words vitamin E antioxidants meta-analysis systematic review cardiovascular disease
This research was performed by the Southern California Evidence-Based Practice Center based at RAND, Santa Monica, Calif under contract to the Agency for Healthcare Research and Quality (contract no. 290-97-0001). The research was requested and funded by The National Center for Complementary and Alternative Medicine, National Institutes of Health. The authors of this article are responsible for its contents, including any clinical or treatment recommendations. No statement in this article should be construed as an endorsement by an official position of the Agency for Healthcare Research and Quality or of The National Center for Complementary and Alternative Medicine, National Institutes of Health, or of the U.S. Department of Health and Human Services.
Dr. Shekelle is a Senior Research Associate of the Veterans Affairs Health Services Research and Development Service.
American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Tex: American Heart Association; 2002.
Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I. General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–53.
Jha P, Flather M, Lonn E, et al. The antioxidant vitamins and cardiovascular disease: a critical review of epidemiologic and clinical trial data. Ann Intern Med. 1995;123:860–72.
Diplock AT. Antioxidant nutrients and disease prevention. Am J Clin Nutr. 1991;53:S189-S93.
Hennekens CH, Gaziano JM. Antioxidants and heart disease: epidemiology and clinical evidence. Clin Cardiol. 1993;16(4 suppl):I10-I15.
Maxwell S. Antioxidant vitamin supplements. Update of their potential benefits and possible risks. Drug Safety. 1999;21:253–66.
Clifton PM. Antioxidant vitamins and coronary heart disease risk. Curr Opin Lipidol. 1995;6:20–4.
Asplund K. Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review. J Intern Med. 2002;251:372–92.
Tribble DL. Antioxidant consumption and risk of coronary heart disease. Emphasis on vitamin C, vitamin E, and beta-carotene: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;99:591–5.
Shekelle P, Morton S, Hardy M. Effect of Supplemental Antioxidants Vitamin C, Vitamin E, and Coenzyme Q10 for the Prevention and Treatment of Cardiovascular Disease. Evidence Report/Technology Assessment no. 83 (Prepared by Southern California RAND Evidence-Based Practice Center, under contract no. 290-97-0001). AHRQ Publication no. 03-E043. Rockville, Md: Agency for Health-care Research and Quality; 2003.
McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of the grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet. 2000;356:1228–31.
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–12.
Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609–13.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. San Diego, Calif: Academic Press; 1985.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
Leppala JM, Virtamo J, Fogelholm R, et al. Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol. 2000;20:230–5.
de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group Primary Prevention Project. Lancet. 2001;357:89–95.
Salonen JT, Nyyssonen K, Salonen R, et al. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Int Med. 2000;248:377–86.
Mark SD, Wang W, Fraumeni JF, et al. Do nutritional supplements lower the risk of stroke or hypertension? Epidemiology. 1998;9:9–15.
Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356:1213–8.
Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease. Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781–6.
Haeger K. The treatment of peripheral occlusive arterial disease with alpha-tocopherol as compared with vasodilator agents and antiprothrombin (dicumarol). Vasc Dis. 1968;5:199–213.
Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:154–60.
GISSI-Prevenzione Investigators. (Gruppo Italiano per lo Studio della Sopravvianza nell’Infarto Miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet. 1999;354:447–55.
Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet. 1997;349:1715–20.
MRC/BHF Heart Protection Study Collaborative group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23–33.
Haeger K. Letter: vitamin E in intermittent claudication. Lancet. 1974;1:1352.
Gillilan RE, Mondell B, Warbasse JR. Quantitative evaluation of vitamin E in the treatment of angina pectoris. Am Heart J. 1977;93:444–9.
Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins Probucol Study Group. N Engl J Med. 1997;337:365–72.
Virtamo J, Rapola JM, Ripatti S, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med. 1998;158:668–75.
Rapola JM, Virtamo J, Ripatti S, et al. Effects of alpha tocopherol and beta carotene supplements on symptoms, progression, and prognosis of angina pectoris. Heart. 1998;79:454–8.
Brown BG, Xue-Qiao Z, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–92.
Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288:2432–40.
Ness A, Smith GD. Mortality in the CHAOS trial. Cambridge Heart Antioxidant Study. Lancet. 1999;353:1017–8.
Singh RB, Niaz MA, Rastogi SS, Rastogi S. Usefulness of antioxidant vitamins in suspected acute myocardial infarction (the Indian experiment of infarct survival-3). Am J Cardiol. 1996;77:232–6.
Sisto T, Paajanen H, Metsa-Ketela T, Harmoinen A, Nordback I, Tarkka M. Pretreatment with antioxidants and allopurinol diminishes cardiac onset events in coronary artery bypass grafting. Ann Thorac Surg. 1995;59:1519–23.
Singh RB, Wander GS, Rastogi A, et al. Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction. Cardiovasc Drugs Ther. 1998;12:347–53.
Kaikkonen J, Kosonen L, Nyyssonen K, et al. Effect of combined coenzyme Q10 and d-alpha-tocopheryl acetate supplementation on exercised-induced lipid peroxidation and muscular damage: a placebo-controlled double-blind study in marathon runners. Free Radic Res. 1998;13:1528–33.
Wen Y, Cooke T, Feely J. The effect of pharmacological supplementation with vitamin C on low-density lipoprotein oxidation. Br J Clin Pharmacol. 1997;44:94–7.
Porkkala-Sarataho E, Salonen JT, Nyyssonen K, et al. Long-term effects of vitamin E, vitamin C, and combined supplementation on urinary 7-hydro-8-oxo-2′-deoxyguanosine, serum cholesterol oxidation products, and oxidation resistance of lipids in nondepleted men. Arterioscler Thromb Vasc Biol. 2000;20:2087–93.
Raitakari OT, McCredie RJ, Witting P, et al. Coenzyme Q improves LDL resistance to
oxidation but does not enhance endothelial function in hypercholesterolemic young adults. Free Radic Biol Med. 2000;28:1100–5.
Iino K, Abe K, Kariya S, Kimura H, Kusaba T. A controlled, double-blind study of dl-alpha-tocopheryl nicotinate (Juvela-Nicotinate) for treatment of symptoms in hypertension and cerebral arteriosclerosis. Jpn Heart J. 1977;18:277–83.
Kaikkonen J, Nyyssonen K, Tomasi A, et al. Antioxidative efficacy of parallel and combined supplementation with coenzyme Q10 and d-alpha-tocopherol in mildly hypercholesterolemic subjects: a randomized placebo-controlled clinical study. Free Radic Res. 2000;33:329–40.
Vivekananthan DP. Use of antioxidant vitamins for the prevention of cardiovascular disease. Lancet. 2003;361:2017–23.
Morris CD, Carson S. Routine vitamin supplementation to prevent cardiovascular disease. A summary of the evidence for the U.S. Preventive Services Task Force. Ann Int Med. 2003;139:56–70.
Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282:1054–60.
Balk EM, Bonis PA, Moskowitz H, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA. 2002;287:2973–82.
PubMed CrossRef Copyright information
© Society of General Internal Medicine 2004